0.5858
price down icon6.87%   -0.0432
after-market After Hours: .61 0.0242 +4.13%
loading
BiomX Inc stock is traded at $0.5858, with a volume of 176.83K. It is down -6.87% in the last 24 hours and down -12.40% over the past month. BiomX Inc., a clinical stage company, develops bacteriophage-based therapies for the treatment and prevention of diseases from the microbiome. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), liver, primary sclerosing cholangitis, and cancer. The company's lead product candidate BX001, which is in phase I that helps to modify the appearance of skin in various skin types, including oily and acne-prone skin type; BX002, a therapeutic phage product to treat IBD; BX003, targets bacteria associated with progressive liver disorder (PSC), a rare inflammatory liver disease; and CRC, targets strains of bacteria found in colorectal cancer tumors. The company has license agreement collaboration with The Weizmann Institute of Science to develop, test, manufacture, produce, and sell microbiome-based therapeutic product candidate; Takeda, develops formulations for phage therapy manufacturing intermediates and for the final form to be administered; Keio University and JSR Corporation, a set of bacterial targets for the development and commercialization of phage therapies to treat IBD; and Janssen Research & Development, LLC to utilize XMarker microbiome-based biomarker discovery platform. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.
See More
Previous Close:
$0.629
Open:
$0.619
24h Volume:
176.83K
Relative Volume:
1.49
Market Cap:
$15.72M
Revenue:
-
Net Income/Loss:
$-26.56M
P/E Ratio:
-0.9012
EPS:
-0.65
Net Cash Flow:
$-22.29M
1W Performance:
+4.72%
1M Performance:
-12.40%
6M Performance:
-37.17%
1Y Performance:
-83.26%
1-Day Range:
Value
$0.5625
$0.619
1-Week Range:
Value
$0.477
$0.70
52-Week Range:
Value
$0.477
$4.99

BiomX Inc Stock (PHGE) Company Profile

Name
Name
BiomX Inc
Name
Phone
972 7 23942377
Name
Address
7 Pinhas Sapir Street, 2nd Floor, Ness Ziona
Name
Employee
73
Name
Twitter
@BiomX_Inc
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
PHGE's Discussions on Twitter

Compare PHGE with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PHGE
BiomX Inc
0.5858 15.72M 0 -26.56M -22.29M -0.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

BiomX Inc Stock (PHGE) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-15-21 Initiated Ladenburg Thalmann Buy

BiomX Inc Stock (PHGE) Latest News

pulisher
01:22 AM

What is HC Wainwright’s Forecast for BiomX Q1 Earnings? - Defense World

01:22 AM
pulisher
Apr 02, 2025

HC Wainwright Issues Positive Forecast for BiomX (NYSEAMERICAN:PHGE) Stock Price - Defense World

Apr 02, 2025
pulisher
Apr 01, 2025

Earnings call transcript: Biomx Q1 2025 sees potential breakthrough in phage therapy - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Biomx stock plunges to 52-week low, hits $0.48 - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Biomx stock plunges to 52-week low, hits $0.48 By Investing.com - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure - GlobeNewswire

Apr 01, 2025
pulisher
Apr 01, 2025

BiomX stock target soars to $21 on Phase 2 trial success - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

Critical Audit Alert: BiomX Receives Going Concern OpinionWhat This Means - Stock Titan

Apr 01, 2025
pulisher
Mar 31, 2025

BiomX Announces Positive Phase 2 Trial Results - TipRanks

Mar 31, 2025
pulisher
Mar 31, 2025

BiomX reports progress in diabetic ulcer treatment By Investing.com - Investing.com Australia

Mar 31, 2025
pulisher
Mar 31, 2025

BiomX reports progress in diabetic ulcer treatment - Investing.com India

Mar 31, 2025
pulisher
Mar 31, 2025

BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO) - MarketScreener

Mar 31, 2025
pulisher
Mar 31, 2025

BiomX Announces Positive Topline Results from Phase 2 Trial - GlobeNewswire

Mar 31, 2025
pulisher
Mar 31, 2025

Major Clinical Success: BiomX's New Drug Shows Promise in Preventing Diabetic Amputations - Stock Titan

Mar 31, 2025
pulisher
Mar 27, 2025

Phage Therapy Market Know the Scope and Trends - openPR

Mar 27, 2025
pulisher
Mar 26, 2025

BiomX (PHGE) Expected to Announce Earnings on Wednesday - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

BiomX Inc Reports Q4 2024 EPS of -$2.56, Revenue at $0.00 Millio - GuruFocus

Mar 25, 2025
pulisher
Mar 25, 2025

BiomX Inc. Secures $12 Million in Financing to Advance Clinical Trials for BX004 and BX211 - Nasdaq

Mar 25, 2025
pulisher
Mar 25, 2025

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates - GlobeNewswire

Mar 25, 2025
pulisher
Mar 25, 2025

Earnings Scheduled For March 25, 2025 - Benzinga

Mar 25, 2025
pulisher
Mar 20, 2025

BiomX (PHGE) Expected to Announce Quarterly Earnings on Tuesday - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - GlobeNewswire

Mar 19, 2025
pulisher
Mar 19, 2025

BiomX Inc. to Report Q4 and Full Year 2024 Financial Results on March 25, 2025 - Nasdaq

Mar 19, 2025
pulisher
Mar 09, 2025

BiomX’s $12 Million Financing - Global Legal Chronicle

Mar 09, 2025
pulisher
Mar 05, 2025

BiomX Inc. secures $12 million from recent offerings - Investing.com India

Mar 05, 2025
pulisher
Mar 04, 2025

Biomx raises $12M to advance phage therapy for CF infections - Cystic Fibrosis News Today

Mar 04, 2025
pulisher
Feb 27, 2025

BiomX Announces $12M Funding for BX004 Study - TipRanks

Feb 27, 2025
pulisher
Feb 26, 2025

BiomX announces series of financings for aggregate gross proceeds of $12M - MSN

Feb 26, 2025
pulisher
Feb 26, 2025

BiomX Announces a Series of Financings for Aggregate Gross Proceeds of $12 Million - GlobeNewswire

Feb 26, 2025
pulisher
Feb 26, 2025

Can BiomX's $12M Financing Push Its Cystic Fibrosis Treatment to the Finish Line? - StockTitan

Feb 26, 2025
pulisher
Feb 18, 2025

BiomX (NYSEMKT:PHGE) Trading Up 22.3% – Still a Buy? - Defense World

Feb 18, 2025
pulisher
Feb 06, 2025

Microbiomes Market to Grow by USD 824.3 Million (2025-2029) with Rising Disease Prevalence Boosting the Market, Report on How AI is Redefining Market LandscapeTechnavio - The Malaysian Reserve

Feb 06, 2025
pulisher
Jan 30, 2025

BiomX (NYSEAMERICAN:PHGE) Stock Price Down 1.3% – What’s Next? - Defense World

Jan 30, 2025
pulisher
Jan 26, 2025

Barclays PLC Has $26,000 Position in BiomX Inc. (NYSEMKT:PHGE) - Defense World

Jan 26, 2025
pulisher
Jan 23, 2025

Phage Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 20+ Key Companies | DelveInsight - GlobeNewswire Inc.

Jan 23, 2025
pulisher
Jan 23, 2025

Phage Therapies Clinical Trial Pipeline Shows Potential - GlobeNewswire

Jan 23, 2025
pulisher
Jan 11, 2025

Barclays PLC Sells 225,000 Shares of BiomX Inc. (NYSEMKT:PHGE) - Defense World

Jan 11, 2025
pulisher
Jan 10, 2025

HC Wainwright Reaffirms Buy Rating for BiomX (NYSEAMERICAN:PHGE) - Defense World

Jan 10, 2025
pulisher
Jan 07, 2025

BiomX (NYSEMKT:PHGE) Stock Price Down 1.3% – Here’s Why - Defense World

Jan 07, 2025
pulisher
Dec 18, 2024

BiomX Inc. Regains Compliance with NYSE American Listing Standards - Defense World

Dec 18, 2024
pulisher
Dec 16, 2024

BiomX regains NYSE compliance - Investing.com

Dec 16, 2024
pulisher
Dec 16, 2024

BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards - The Manila Times

Dec 16, 2024
pulisher
Dec 16, 2024

BiomX Regains NYSE American Listing Compliance After Meeting All Standards - StockTitan

Dec 16, 2024

BiomX Inc Stock (PHGE) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Cap:     |  Volume (24h):